Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 2 · 50%

Overall survival† · people with cutaneous melanoma

BRAF plus MEK inhibitors leads to lower overall survival† compared with BRAF inhibitors (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.7 [0.59, 0.82]
1784 participants
High

Progression‐free survival · people with cutaneous melanoma

BRAF plus MEK inhibitors probably leads to lower progression‐free survival† compared with BRAF inhibitors (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
HR 0.56 [0.44, 0.71]
1784 participants
Moderate

Tumour response · people with cutaneous melanoma

BRAF plus MEK inhibitors leads to higher tumour response compared with BRAF inhibitors (high certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.32 [1.2, 1.46]
1784 participants
High

Toxicity (≥ G3) · people with cutaneous melanoma

BRAF plus MEK inhibitors showed no clear difference in toxicity (≥ G3) compared with BRAF inhibitors (moderate certainty).

1 finding from 1 review

Systemic treatments for metastatic cutaneous melanoma 2018 · Cochrane Headline outcomes only
RR 1.01 [0.85, 1.2]
1774 participants
Moderate